Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test predict who will get diabetes from steroids?

NCT ID NCT04840693

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic and metabolic markers that explain why some people develop diabetes, high blood pressure, or bone loss from glucocorticoids while others do not. Researchers will analyze blood and urine samples from up to 600 participants, including those with excess glucocorticoids, adrenal insufficiency, and control groups. The goal is to create a tool that predicts individual risks, helping doctors personalize treatment and monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * an endogenous hypercortisolism (group 1) * a disease justifying the next start of glucocorticoid therapy (group 2) * chronic adrenal insufficiency (group 3) * subjects with either diabetes, hypertension or osteoporosis, but without glucocorticoid excess (control group) * patients will have to be affiliated to a social security scheme * patients should be able to understand the study and able to express their consent Exclusion Criteria: * patients with reduced life expectancy, less than 2 years * pregnant or lactating women * patients refusing the protocol * patients under state medical assistance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult adrenal insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult adrenal insufficiency Adult glucocorticoid excess

Contacts and locations

Locations

  • Hôpital Cochin

    Paris, 75014, France